CNTX

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for solid tumors, particularly those affecting women. Headquartered in Philadelphia, Pennsylvania, the company focuses on identifying and developing therapies that target specific molecular profiles of cancers. Context Therapeutics' lead program, CTIM-76, is a Claudin 6 (CLDN6)-targeted antibody-drug conjugate being developed for CLDN6-positive solid tumors including ovarian, endometrial, and testicular cancers. The company uses proprietary biomarker-driven approaches to identify patient populations most likely to benefit from its therapies. Context Therapeutics aims to advance precision oncology by developing targeted treatments that address significant unmet needs in cancers with limited treatment options.